Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Cyril Berthet, Pharmaco-imaging Unit Director & Director of Pharmimage 26 septembre 2019 – 17h
Exciting recent developments have proven the unique promise offered by Targeted Radionuclide Therapy (TRT) for better precision medicine. Whether given alone or in combination, TRT and immunotherapy will have an important role to play in the treatment of cancer patients in the future.
Dr. Cyril Berthet will present the tools & expertise available today for the preclinical assessment of TRT. Discover how to facilitate the translation of new targeted radionuclide therapies into clinical practice. Find out about preclinical targeted radiopharmaceuticals projects, including combination studies with chemotherapies or immune checkpoint inhibitors!
Key learning objectives
Introduction to TRT
Design & implementation of the radionuclide labeling of biological molecules of interest
Binding study to select the preclinical models and population of patients expressing the target of interest
Whole body biodistribution to evaluate the kinetic of in vivo specific binding
Evaluation of targeted radiotherapy efficacy
Benefit of radiotherapy and immunotherapy or chemotherapy combinationVitro/Vivo assays developed by Oncodesign for routine assessment of molecules.
About our speaker Cyril Berthet
Cyril Berthet is Pharmaco-imaging Unit Director & Director of Pharmimage Operations at Oncodesign. He holds a PhD in Molecular and Cellular Biology from the University of Lyon, France. In 2002, he joined the Mouse Cancer Genetics Program at the National Cancer Institute in Frederick, US as a Research Associate. He joined Oncodesign in 2007 as a project leader and now manages strategic partnerships in therapeutic and biomarker discovery.
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260